Disease Info Card

Microangiopathic Hemolytic Anemia

Information about Microangiopathic Hemolytic Anemia: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Microangiopathic Hemolytic Anemia

Most recent studies have shown that Microangiopathic Hemolytic Anemia shares some biological mechanisms with adenocarcinoma, anemia, anemia-hemolytic, carcinoma, disease-of-capillaries, disseminated-intravascular-coagulation, hemolysis-(disorder), hemolytic-uremic-syndrome, hypertensive-disease, kidney-failure, kidney-failure-acute, malignant-neoplasms, neoplasms, purpura, purpura-thrombotic-thrombocytopenic, thrombocytopenic-purpura, thrombosis, thrombotic-microangiopathies, uremia-syndrome, von-willebrand-disease.

Among the many pathways, these few ones have gauged particular interests from scientists studying Microangiopathic Hemolytic Anemia, and have been seen in publications frequently: Blood Coagulation, Cell Adhesion, Cell Killing, Cell Proliferation, Coagulation, Complement Activation, Diuresis, Endothelial Cell Proliferation, Fibrinolysis, Glomerular Filtration, Hemostasis, Hypersensitivity, Inflammatory Response, Localization, Pathogenesis, Platelet Activation, Platelet Aggregation, Secretion, Vasoconstriction, Virulence

Quite a number of genes have been found to play important roles in Microangiopathic Hemolytic Anemia, such as ACE, ADAMTS13, AP3B1, C3, CAPG, CD46, CFH, CFI, F2, HP, MYH9, PREP, SH3BP4, SLC25A10, ST8SIA2, THBD, VWF, ZFP36. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.